drugset / Trial / NCT00274469

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

NCT00274469

Phase 2 Completed 205 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.

Timeline

Start
2006-02-06
Primary completion
2008-01-10
Completion
2017-01-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastrozole Other / unclassified 1 mg Oral
Subject Fulvestrant Small molecule 500 mg Intramuscular

Indications